EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)Frank Tacke, Dror Dicker, Paul Horn et al.|Journal of Hepatology|2024Cited by 1.6k
Joint international consensus statement for ending stigma of obesityFrancesco Rubino, John B. Dixon, Camilo Boza et al.|Nature Medicine|2020Cited by 1.1k
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive SummaryFrank Tacke, Dror Dicker, Paul Horn et al.|Diabetologia|2024Cited by 150
Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 TrialsHiddo J.L. Heerspink, David Z.I. Cherney, Ellen M. Apperloo et al.|Diabetes Care|2023Cited by 89
POS-336 SEMAGLUTIDE 2.4 MG AND 1.0 MG IMPROVED ALBUMINURIA IN ADULTS WITH OVERWEIGHT/OBESITY AND TYPE 2 DIABETES IN STEP 2Hiddo J.L. Heerspink, David Z.I. Cherney, Ellen M. Apperloo et al.|Kidney International Reports|2022Cited by 2